92 related articles for article (PubMed ID: 2693107)
21. Late cytomegalovirus pneumonia in adult allogeneic blood and marrow transplant recipients.
Nguyen Q; Champlin R; Giralt S; Rolston K; Raad I; Jacobson K; Ippoliti C; Hecht D; Tarrand J; Luna M; Whimbey E
Clin Infect Dis; 1999 Mar; 28(3):618-23. PubMed ID: 10194088
[TBL] [Abstract][Full Text] [Related]
22. Intravenous hyperimmune globulin prophylaxis against cytomegalovirus interstitial pneumonitis after allogenic bone marrow transplantation.
Jacobsen N; Schäfer U; Ostendorf P; Kubaneck B; Wolf H
Tokai J Exp Clin Med; 1985 Jun; 10(2-3):193-5. PubMed ID: 3010510
[TBL] [Abstract][Full Text] [Related]
23. Randomized controlled trial of sequential intravenous and oral ganciclovir versus prolonged intravenous ganciclovir for long-term prophylaxis of cytomegalovirus disease in high-risk cytomegalovirus-seronegative liver transplant recipients with cytomegalovirus-seropositive donors.
Winston DJ; Busuttil RW
Transplantation; 2004 Jan; 77(2):305-8. PubMed ID: 14742998
[TBL] [Abstract][Full Text] [Related]
24. Pulmonary infections after bone marrow transplant.
Cunningham I
Semin Respir Infect; 1992 Jun; 7(2):132-8. PubMed ID: 1439322
[TBL] [Abstract][Full Text] [Related]
25. Ganciclovir three times per week is not adequate to prevent cytomegalovirus reactivation after T cell-depleted marrow transplantation.
Przepiorka D; Ippoliti C; Panina A; Goodrich J; Giralt S; van Besien K; Mehra R; Deisseroth AB; Andersson B; Luna M
Bone Marrow Transplant; 1994 Apr; 13(4):461-4. PubMed ID: 8019472
[TBL] [Abstract][Full Text] [Related]
26. Preemptive treatment for cytomegalovirus viremia to prevent cytomegalovirus disease in solid organ transplant recipients.
Strippoli GF; Hodson EM; Jones C; Craig JC
Transplantation; 2006 Jan; 81(2):139-45. PubMed ID: 16436954
[TBL] [Abstract][Full Text] [Related]
27. Combined antiviral and immunoglobulin therapy as prophylaxis against cytomegalovirus infection after heart transplantation.
Valenza M; Czer LS; Pan SH; Aleksic I; Freimark D; Harasty DA; Admon D; Barath P; Blanche C; Trento A
J Heart Lung Transplant; 1995; 14(4):659-65. PubMed ID: 7578172
[TBL] [Abstract][Full Text] [Related]
28. Cytomegalovirus infection after bone marrow transplantation in children.
Castagnola E; Cappelli B; Erba D; Rabagliati A; Lanino E; Dini G
Hum Immunol; 2004 May; 65(5):416-22. PubMed ID: 15172440
[TBL] [Abstract][Full Text] [Related]
29. Cytomegalovirus seronegative platelets and leukocyte-poor red blood cells from random donors can prevent primary cytomegalovirus infection after bone marrow transplantation.
Verdonck LF; de Graan-Hentzen YC; Dekker AW; Mudde GC; de Gast GC
Bone Marrow Transplant; 1987 Jun; 2(1):73-8. PubMed ID: 2844337
[TBL] [Abstract][Full Text] [Related]
30. Interstitial pneumonia after allogeneic and autologous bone marrow transplantation.
Funada H; Harada M; Yoshida T; Hattori K
Jpn J Clin Oncol; 1984 Dec; 14 Suppl 1():519-30. PubMed ID: 6097710
[TBL] [Abstract][Full Text] [Related]
31. Higher risk of cytomegalovirus and aspergillus infections in recipients of T cell-depleted unrelated bone marrow: analysis of infectious complications in patients treated with T cell depletion versus immunosuppressive therapy to prevent graft-versus-host disease.
van Burik JA; Carter SL; Freifeld AG; High KP; Godder KT; Papanicolaou GA; Mendizabal AM; Wagner JE; Yanovich S; Kernan NA
Biol Blood Marrow Transplant; 2007 Dec; 13(12):1487-98. PubMed ID: 18022579
[TBL] [Abstract][Full Text] [Related]
32. Management of human cytomegalovirus infection and disease after allogeneic bone marrow transplantation.
Stocchi R; Ward KN; Fanin R; Baccarani M; Apperley JF
Haematologica; 1999 Jan; 84(1):71-9. PubMed ID: 10091394
[TBL] [Abstract][Full Text] [Related]
33. [Effectiveness of preemptive therapy with ganciclovir in recipients of renal transplants at high risk (R-/D+) for the development of cytomegalovirus disease].
Aranda-Verástegui F; Alberú J; Soto-Ramírez LE; González-Aguirre H; Muñoz Trejo T; Mancilla E; Díliz H; Correa-Rotter R; Sierra-Madero J
Rev Invest Clin; 2002; 54(3):198-203. PubMed ID: 12183888
[TBL] [Abstract][Full Text] [Related]
34. Significant reduction of cytomegalovirus (CMV) disease by prophylaxis with CMV hyperimmune globulin plus oral acyclovir.
Einsele H; Vallbracht A; Friese M; Schmidt H; Haen M; Dopfer R; Niethammer D; Waller HD; Ehninger G
Bone Marrow Transplant; 1988 Nov; 3(6):607-17. PubMed ID: 2850830
[TBL] [Abstract][Full Text] [Related]
35. Management of infectious complications of bone marrow transplantation.
Wingard JR
Oncology (Williston Park); 1990 Feb; 4(2):69-75; discussion 76, 81-2. PubMed ID: 2143670
[TBL] [Abstract][Full Text] [Related]
36. Cytomegalovirus pneumonia: presentation, diagnosis, and treatment.
Ljungman P
Semin Respir Infect; 1995 Dec; 10(4):209-15. PubMed ID: 8668848
[TBL] [Abstract][Full Text] [Related]
37. Prophylaxis of CMV infection in bone marrow transplant recipients by hyperimmune CMV gamma-globulin.
Condie RM; O'Reilly RJ
Dev Biol Stand; 1982; 52():501-13. PubMed ID: 6299859
[TBL] [Abstract][Full Text] [Related]
38. Strategies to prevent or control infections after bone marrow transplants.
Karp JE; Merz WG; Dick JD; Saral R
Bone Marrow Transplant; 1991 Jul; 8(1):1-6. PubMed ID: 1912952
[TBL] [Abstract][Full Text] [Related]
39. Prevention of primary cytomegalovirus disease in organ transplant recipients with oral ganciclovir or oral acyclovir prophylaxis.
Rubin RH; Kemmerly SA; Conti D; Doran M; Murray BM; Neylan JF; Pappas C; Pitts D; Avery R; Pavlakis M; Del Busto R; DeNofrio D; Blumberg EA; Schoenfeld DA; Donohue T; Fisher SA; Fishman JA
Transpl Infect Dis; 2000 Sep; 2(3):112-7. PubMed ID: 11429021
[TBL] [Abstract][Full Text] [Related]
40. Bedside leukoreduction of cellular blood components in preventing cytomegalovirus transmission in allogeneic bone marrow transplant recipients: a retrospective study.
Narvios AB; Lichtiger B
Haematologica; 2001 Jul; 86(7):749-52. PubMed ID: 11454531
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
